What you'll pay at Lincolnshire Hip

Lincolnshire Hip publishes a confirmed package price of £2,995 per hip ChondroFiller injection, available at two local clinic sites — Grantham and Sleaford — so patients across Lincolnshire and the surrounding area can access the treatment without travelling to London.

That figure is all-inclusive. The package covers:

• Initial specialist consultation and diagnostic imaging review
• The ChondroFiller collagen scaffold product itself
• Ultrasound-guided injection, delivered as an outpatient appointment
• IV antibiotic cover during the procedure
• A 6-week follow-up appointment

There is no additional charge for the components listed above, and no GP referral is needed — patients book directly with Lincolnshire Hip.

The £2,995 price sits marginally below the single-box headline tariff published by London Cartilage Clinic (£3,000), though the more meaningful distinction for most Lincolnshire patients is the absence of travel time and cost associated with a London appointment.

Published fees may be updated, so patients should confirm current pricing directly with the clinic before proceeding. The figures above reflect the tariff listed on the Lincolnshire Hip Locations & Cost page at the time of writing.

Why ChondroFiller costs more than standard hip injections

The price difference between ChondroFiller and standard hip injections is structural, not arbitrary. Most patients will have encountered hyaluronic acid (viscosupplementation) or corticosteroid injections before — both are generic injectables held in clinic stock, typically costing £200–£500 per course for hyaluronic acid, with corticosteroid positioned as a short-term option for acute symptom control. Neither acts as a regenerative scaffold.

ChondroFiller occupies a different regulatory category entirely. It is a CE-marked Class III medical device — the highest-risk classification under UK and EU medical device regulation. That classification reflects what the product does inside the joint: once placed under ultrasound guidance, the collagen solution gels in situ and recruits the patient's own progenitor cells through a process called acellular matrix-induced chondrogenesis, supporting the body's own repair processes rather than simply lubricating or temporarily dampening inflammation.

Class III status carries supply-chain consequences. Each unit is manufactured by Meidrix Biomedicals GmbH in Germany and imported under a separate prescription for each individual patient — it is not a commodity product ordered by the box and stored on a shelf. That per-patient import pathway adds regulatory overhead and logistics cost that commodity injectables do not carry.

The price gap versus standard hip injections therefore reflects classification and supply structure, not a mark-up on a generic product.

How defect size affects the total price

Pricing scales with the number of ChondroFiller units required, which is determined by the surface area of the cartilage defect — not by joint location or age alone. The tier structure across UK providers is as follows:

| Boxes | Defect area covered | Guide cost | |-------|--------------------|-----------| | 1 box | Up to approximately 3 cm² | ~£3,000 | | 2 boxes | Up to approximately 4.5 cm² | ~£5,500 | | 3 boxes | Up to approximately 6 cm² | ~£8,000 |

Complex or unusually large cases can occasionally reach approximately £9,800, though this sits at the upper limit of reported tariffs.

For most patients, a single box is sufficient. Focal hip cartilage defects — the primary indication — tend to be smaller lesions where one unit provides adequate coverage, placing the majority of patients toward the lower end of this range.

For context, arthroscopic theatre delivery under general anaesthetic is priced separately at approximately £9,500, making the ultrasound-guided outpatient injection the more cost-accessible route for eligible patients. The two pathways involve different clinical settings and are not interchangeable based on cost alone.

The number of boxes needed cannot be confirmed from symptoms alone. The Lincolnshire Hip team advises on unit requirements following MRI or scan review, so a firm treatment cost is established before any commitment is made.

Why the NHS does not fund ChondroFiller for the hip

ChondroFiller is not available through the NHS, in Lincolnshire or anywhere else in England — and the reason is commissioning structure rather than an absence of clinical evidence.

NICE has not completed a technology appraisal for ChondroFiller in any joint. The only cartilage cell therapy with NHS funding is autologous chondrocyte implantation (ACI), approved under NICE TA477 in October 2017 — and that approval covers the knee only. No equivalent appraisal exists for the hip.

The commissioned NHS pathway for hip patients runs from conservative management — physiotherapy, weight management, analgesia — directly to total hip replacement. There is no funded biological joint-preservation intermediate. A patient with focal hip cartilage damage who is not yet at replacement stage has no NHS pathway to bridge that gap: the options are to self-fund a joint-preservation treatment privately, obtain insurer cover with prior authorisation, or wait until replacement becomes clinically appropriate.

ChondroFiller sits outside NHS commissioning primarily because no UK health-technology appraisal has been completed for it. Its Class III device classification adds regulatory complexity, but classification alone does not determine NHS access. What matters for commissioning is a completed NICE evaluation, and that process has not run for this indication. The clinical evidence base and the funding decision are separate questions.

Insurance cover and self-pay options

Private medical insurance may cover ChondroFiller hip injection, but the emphasis belongs firmly on may. Bupa, Aviva, and WPA are the insurers most often reported to have approved the procedure — though individual policy terms vary considerably, and approval rates across the wider patient population are not published. No insurer can be named as reliably or routinely approving the treatment.

For patients exploring this route, the relevant CCSD billing codes are W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy). Checking with your insurer that both codes fall within your policy's scope — and obtaining written pre-authorisation before treatment begins — is essential, not optional. Pre-authorisation granted verbally or assumed from a general policy summary carries no clinical or financial weight.

Most patients proceed as self-pay. For them, the £2,995 Lincolnshire Hip package price (set out in section one) is all-inclusive, so there are no unexpected add-ons to negotiate after the initial quote.

Lincolnshire Hip accepts patients without referral. Anyone wishing to discuss eligibility, timing, or payment before booking can contact the clinic directly.

Who is suitable and how to take the next step

ChondroFiller hip injection is aimed at a specific clinical picture: focal Grade III or IV articular cartilage damage in the hip joint, confirmed on imaging. It is not a treatment for end-stage, diffuse hip osteoarthritis where the joint surface is globally compromised — patients in that situation are more likely to be discussing hip replacement than joint-preservation injection.

Suitability is established through imaging review at the Grantham or Sleaford clinics. Published data suggest a modified Harris Hip Score improvement of approximately 30 points in suitable candidates; it is worth noting that the evidence base for the hip specifically remains less extensive than for the knee, with the majority of trial data being knee-derived. That limitation does not invalidate the hip indication, but it should be part of an honest clinical discussion.

Prof Paul Y.F. Lee, who leads the service at Lincolnshire Hip, has a specialist focus on hip cartilage preservation — a focus that informs both patient selection and the decision about whether ChondroFiller or a different pathway better fits the stage of disease.

For anyone whose symptoms and imaging point toward a focal-defect profile, the practical next step is a consultation at Lincolnshire Hip, part of the MSK Doctors specialist group. That appointment produces a clear suitability decision, a confirmed price, and — where appropriate — a treatment plan with no open-ended costs to negotiate afterwards.